CCT245737
CCT245737 (SRA737) is an orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM.
Product Specifications
CAS Number
1489389-18-5
Product Name Alternative
SRA737
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Checkpoint Kinase (Chk)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CCT245737.html
Purity
99.48
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
FC(F)(F)C(C=NC(NC1=CN=C(C#N)C=N1)=C2)=C2NC[C@H]3CNCCO3
Molecular Formula
C16H16F3N7O
Molecular Weight
379.34
Precautions
H315, H319, H335
References & Citations
[1]Osborne JD, et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R) -5- ((4- ((Morpholin-2-ylmethyl) amino) -5- (trifluoromethyl) pyridin-2-yl) amino) pyrazine-2-carbonitrile (CCT245737) . J Med Chem. 2016 Jun 9;59 (11) :5221-37.|[2]Walton MI, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Chk1; Chk2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
KN206629BN 1 Kit
Interleukin 34 (IL34) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 
